Ste-Marie L - Search Results

1

Risedronate, a highly effective, short-term oral treatment for Paget's disease: a dose-response study.

Brown JP, Hosking DJ, Ste-Marie L, Johnston CC Jr, Reginster J, Ryan WG, Johnson TD, Bekker PJ. Brown JP, et al. Calcif Tissue Int. 1999 Feb;64(2):93-9. doi: 10.1007/s002239900584. Calcif Tissue Int. 1999. PMID: 9914313 Clinical Trial.

2

Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis.

Ste-Marie LG, Sod E, Johnson T, Chines A. Ste-Marie LG, et al. Calcif Tissue Int. 2004 Dec;75(6):469-76. doi: 10.1007/s00223-004-0039-7. Epub 2004 Oct 14. Calcif Tissue Int. 2004. PMID: 15478000 Clinical Trial.

3

Positive effect of etidronate therapy is maintained after drug is terminated in patients using corticosteroids.

Brown JP, Olszynski WP, Hodsman A, Bensen WG, Tenenhouse A, Anastassiades TP, Ste-Marie LG, Kendler DL, Hanley DA, Josse R, Hanly JG, Lentle B, Jovaisas A, Ioannidis G, Stephenson GF, Barton I, Pack S, Chines A, Dias R, Adachi JD. Brown JP, et al. J Clin Densitom. 2001 Winter;4(4):363-71. doi: 10.1385/jcd:4:4:363. J Clin Densitom. 2001. PMID: 11748341 Clinical Trial.

4

The impact of educational interventions on modifiable risk factors for osteoporosis after a fragility fracture.

Beaudoin C, Bessette L, Jean S, Ste-Marie LG, Brown JP. Beaudoin C, et al. Osteoporos Int. 2014 Jul;25(7):1821-30. doi: 10.1007/s00198-014-2618-4. Epub 2014 Feb 12. Osteoporos Int. 2014. PMID: 24519745 Clinical Trial.

5

Denosumab compared to other treatments to prevent or treat osteoporosis in individuals at risk of fracture: a systematic review and meta-analysis.

Beaudoin C, Jean S, Bessette L, Ste-Marie LG, Moore L, Brown JP. Beaudoin C, et al. Osteoporos Int. 2016 Sep;27(9):2835-2844. doi: 10.1007/s00198-016-3607-6. Epub 2016 Apr 27. Osteoporos Int. 2016. PMID: 27120345 Review.

6

Factors influencing the treatment of osteoporosis following fragility fracture.

Bessette L, Jean S, Davison KS, Roy S, Ste-Marie LG, Brown JP. Bessette L, et al. Osteoporos Int. 2009 Nov;20(11):1911-9. doi: 10.1007/s00198-009-0898-x. Epub 2009 Mar 31. Osteoporos Int. 2009. PMID: 19333675

7

Predicting subsequent bone density response to intermittent cyclical therapy with etidronate from initial density response in patients with osteoporosis.

Crilly RG, Sebaldt RJ, Hodsman AB, Adachi JD, Brown JP, Goldsmith CH, Hanley DA, Olszynski WO, Ste-Marie LG, Stephenson GF. Crilly RG, et al. Osteoporos Int. 2000;11(7):607-14. doi: 10.1007/s001980070082. Osteoporos Int. 2000. PMID: 11069195

8

The impact of two educational interventions on osteoporosis diagnosis and treatment after fragility fracture: a population-based randomized controlled trial.

Bessette L, Davison KS, Jean S, Roy S, Ste-Marie LG, Brown JP. Bessette L, et al. Osteoporos Int. 2011 Dec;22(12):2963-72. doi: 10.1007/s00198-011-1533-1. Epub 2011 Feb 11. Osteoporos Int. 2011. PMID: 21311871 Clinical Trial.

9

The care gap in diagnosis and treatment of women with a fragility fracture.

Bessette L, Ste-Marie LG, Jean S, Davison KS, Beaulieu M, Baranci M, Bessant J, Brown JP. Bessette L, et al. Osteoporos Int. 2008 Jan;19(1):79-86. doi: 10.1007/s00198-007-0426-9. Epub 2007 Jul 20. Osteoporos Int. 2008. PMID: 17641811

10

Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis.

Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, Kendler DL, Lentle B, Olszynski W, Ste-Marie LG, Tenenhouse A, Chines AA. Adachi JD, et al. N Engl J Med. 1997 Aug 7;337(6):382-7. doi: 10.1056/NEJM199708073370603. N Engl J Med. 1997. PMID: 9241127 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

112 results

Search Page

Filters